Preparation of Inactivated HTLV-III and STLV-III Whole Virus Pilot Vaccines
Abstract
The purpose of this contract was to provide specific reagents and services supporting programs to prevent or treat HIV-1 infection and disease. A major requirement was the preparation of inactivated, whole virus for evaluation as a possible vaccine. Selected strains of HIV-1 and SIV-1 were adapted for optimum production, concentration and partial purification, and effective inactivation. Approximately 28 mg of HIV-1 sub IIIB and 70 mg of SIV-1 sub MNE (E11S) were prepared for this program. In addition, five selected strains of HIV-1 (DOD US clinical isolates) were transmitted to one of five different established cell lines and 73 biological clones were prepared. Also, five isolates of HIV-1 (Northern Thailand) were amplified in human peripheral blood lymphocytes or monocyte-macrophages and were tested for transmission into established cell lines including a chimpanzee T-cell line. The possibility of their use to infect nonhuman primates, e.g., the chimpanzee, will require further experimentation. Several HIV-1 and SIV-1 envelope proteins in their native, non-denatured configuration were prepared. These included 0.512 mg HIV-1 gpl20, 1.967 mg HIV-1 gp160, 0.825 mg SIV-1 gp120 and 1.823 mg SIV-1 p24. Other immunological reagents prepared included monoclonal antibodies specific for 14 different SIV-1 envelope or gag epitopes. Finally, sixteen nonhuman primates belonging to either Macaca nemestrina or Macaca fascicularis species were housed and experimentally manipulated. HIV-1, SIV-1, Vaccine, AIDS, RAI, Biologics Production, Volunteers, Lab Animals, Rodents
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 29, 1993
- Accession Number
- ADA268996
Entities
People
- Mikulas Popovic
- Phillip D. Markham
- Vaniambadi S. Kalyanaraman